Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), has appointed Marc Forth as Chief Executive Officer, effective April 07, 2025. Forth brings over 30 years of healthcare industry experience, notably in commercial and executive leadership.
Forth's impressive background includes serving as President and CEO of AEON Biopharma, where he managed the botulinum toxin type A complex agent ABP-450 development program. Previously, as Senior Vice President at Allergan PLC, he headed the U.S. Neurosciences, Urology and Medical Dermatology Divisions. His 16-year tenure at Allergan involved commercializing BOTOX® Therapeutic and developing marketing strategies for BOTOX® Cosmetic.
Jeune Aesthetics leverages Krystal's FDA-validated gene-delivery platform to address aging skin biology. Forth has been a board member since February 2021 and will now lead the company's expansion in rejuvenative aesthetics.
Jeune Aesthetics, una filiale di Krystal Biotech (NASDAQ: KRYS), ha nominato Marc Forth come Amministratore Delegato, con effetto dal 7 aprile 2025. Forth porta con sé oltre 30 anni di esperienza nel settore sanitario, in particolare nella leadership commerciale ed esecutiva.
Il background impressionante di Forth include il ruolo di Presidente e CEO di AEON Biopharma, dove ha gestito il programma di sviluppo dell'agente complesso di tossina botulinica di tipo A ABP-450. In precedenza, come Vicepresidente Senior presso Allergan PLC, ha guidato le Divisioni Neuroscienze, Urologia e Dermatologia Medica negli Stati Uniti. I suoi 16 anni di permanenza in Allergan hanno comportato la commercializzazione di BOTOX® Therapeutic e lo sviluppo di strategie di marketing per BOTOX® Cosmetic.
Jeune Aesthetics sfrutta la piattaforma di consegna genica validata dalla FDA di Krystal per affrontare la biologia della pelle invecchiata. Forth è stato membro del consiglio di amministrazione da febbraio 2021 e ora guiderà l'espansione dell'azienda nell'estetica rigenerativa.
Jeune Aesthetics, una subsidiaria de Krystal Biotech (NASDAQ: KRYS), ha nombrado a Marc Forth como Director Ejecutivo, con efecto a partir del 7 de abril de 2025. Forth aporta más de 30 años de experiencia en la industria de la salud, especialmente en liderazgo comercial y ejecutivo.
El impresionante historial de Forth incluye su papel como Presidente y CEO de AEON Biopharma, donde gestionó el programa de desarrollo del agente complejo de toxina botulínica tipo A ABP-450. Anteriormente, como Vicepresidente Senior en Allergan PLC, dirigió las divisiones de Neurociencias, Urología y Dermatología Médica en EE. UU. Su permanencia de 16 años en Allergan involucró la comercialización de BOTOX® Therapeutic y el desarrollo de estrategias de marketing para BOTOX® Cosmetic.
Jeune Aesthetics aprovecha la plataforma de entrega de genes validada por la FDA de Krystal para abordar la biología de la piel envejecida. Forth ha sido miembro de la junta desde febrero de 2021 y ahora liderará la expansión de la empresa en estética rejuvenecedora.
Jeune Aesthetics는 Krystal Biotech (NASDAQ: KRYS)의 자회사로, Marc Forth를 CEO로 임명했습니다. 임기는 2025년 4월 7일부터 시작됩니다. Forth는 상업 및 경영 리더십 분야에서 30년 이상의 의료 산업 경험을 보유하고 있습니다.
Forth의 인상적인 경력에는 AEON Biopharma의 사장 및 CEO로 재직하며 보툴리눔 독소 A형 복합체 ABP-450 개발 프로그램을 관리한 경험이 포함됩니다. 이전에는 Allergan PLC의 수석 부사장으로서 미국의 신경과학, 비뇨기과 및 의료 피부과 부서를 이끌었습니다. Allergan에서의 16년 동안 BOTOX® Therapeutic의 상용화와 BOTOX® Cosmetic의 마케팅 전략 개발에 참여했습니다.
Jeune Aesthetics는 Krystal의 FDA 인증 유전자 전달 플랫폼을 활용하여 노화된 피부 생물학을 다룹니다. Forth는 2021년 2월부터 이사회 구성원으로 활동해 왔으며, 이제 회사의 재생 미용 분야 확장을 이끌 것입니다.
Jeune Aesthetics, une filiale de Krystal Biotech (NASDAQ: KRYS), a nommé Marc Forth au poste de Directeur Général, à compter du 7 avril 2025. Forth apporte plus de 30 ans d'expérience dans l'industrie de la santé, notamment dans le leadership commercial et exécutif.
Le parcours impressionnant de Forth comprend son rôle de Président et CEO de AEON Biopharma, où il a géré le programme de développement de l'agent complexe de toxine botulique de type A ABP-450. Auparavant, en tant que Vice-Président Senior chez Allergan PLC, il a dirigé les divisions des neurosciences, de l'urologie et de la dermatologie médicale aux États-Unis. Ses 16 années passées chez Allergan ont impliqué la commercialisation de BOTOX® Therapeutic et le développement de stratégies de marketing pour BOTOX® Cosmetic.
Jeune Aesthetics exploite la plateforme de livraison de gènes validée par la FDA de Krystal pour traiter la biologie de la peau vieillissante. Forth est membre du conseil d'administration depuis février 2021 et dirigera désormais l'expansion de l'entreprise dans le domaine de l'esthétique régénérative.
Jeune Aesthetics, eine Tochtergesellschaft von Krystal Biotech (NASDAQ: KRYS), hat Marc Forth zum Chief Executive Officer ernannt, mit Wirkung zum 7. April 2025. Forth bringt über 30 Jahre Erfahrung in der Gesundheitsbranche mit, insbesondere in der kommerziellen und exekutiven Führung.
Forths beeindruckender Hintergrund umfasst die Position des Präsidenten und CEO von AEON Biopharma, wo er das Entwicklungsprogramm für den Botulinumtoxin-Typ-A-Komplex ABP-450 leitete. Zuvor war er als Senior Vice President bei Allergan PLC für die US-Divisionen Neurowissenschaften, Urologie und medizinische Dermatologie verantwortlich. Seine 16-jährige Tätigkeit bei Allergan umfasste die Kommerzialisierung von BOTOX® Therapeutic und die Entwicklung von Marketingstrategien für BOTOX® Cosmetic.
Jeune Aesthetics nutzt die von der FDA validierte Genlieferplattform von Krystal, um die Biologie der alternden Haut anzugehen. Forth ist seit Februar 2021 Mitglied des Vorstands und wird nun die Expansion des Unternehmens im Bereich der regenerativen Ästhetik leiten.
- Appointment of experienced CEO with 30+ years in healthcare industry
- New CEO brings extensive BOTOX commercialization expertise
- CEO's prior board experience with company since 2021 ensures familiarity with operations
- Strategic leadership addition to drive company's growth in rejuvenative aesthetics
- None.
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune’s board of directors since February 2021.
“I am excited to welcome Marc to the team as we embark on the next stage of growth at Jeune,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “Marc brings decades of leadership experience to Jeune, and I look forward to working with him to maximize the value of our rejuvenative aesthetics platform.”
Mr. Forth brings to Jeune wide-ranging experience as both a corporate and commercial leader in the areas of therapeutics and aesthetics. Prior to joining Jeune, Mr. Forth was President and Chief Executive Officer of AEON Biopharma, where he led the exclusive regional licensure for therapeutic use of botulinum toxin type A complex agent ABP-450 from Daewoong Pharmaceutical Co., Ltd. and then oversaw a comprehensive clinical development program for ABP-450 targeting indications in neurology, gastroenterology, and neuro/psychiatry. Before his time at AEON Biopharma, Mr. Forth was Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Divisions. During his 16-year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within neurosciences, urology and medical dermatology, including BOTOX® Therapeutic. Earlier in his career, Mr. Forth led the planning and execution of the integrated marketing plans for BOTOX® Cosmetic in the United States, where he was instrumental in building out a comprehensive consumer promotional platform. Prior to Allergan, Mr. Forth held positions of increasing responsibility in sales, marketing, and public relations at TAP Pharmaceuticals and WSW Associates. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.
“I am thrilled to be joining Jeune as CEO as it takes the next step forward in its growth journey,” said Mr. Forth. “With Krystal’s FDA-validated gene delivery platform at its core, Jeune is uniquely positioned to meet the growing demand for fundamentally rejuvenative treatments to address aging skin. I look forward to working alongside the talented team to create long-term value, drive investment, and establish Jeune as the leader in rejuvenative aesthetics.”
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit http://www.jeuneinc.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Jeune Aesthetics, Inc., including statements about the growing demand for fundamentally rejuvenative treatments to address aging skin and Jeune being uniquely positioned to meet that demand; plans to create long-term value, drive investment in Jeune, and establish Jeune as the leader in rejuvenative aesthetics; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of Jeune’s investigative products, and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s and Jeune’s views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s and Jeune’s views as of any date subsequent to the date of this press release.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When did Marc Forth join Jeune Aesthetics (KRYS) as CEO?
What is Marc Forth's experience with BOTOX before joining KRYS?
What was Marc Forth's role at AEON Biopharma before joining Jeune Aesthetics?
How long has Marc Forth been associated with Jeune Aesthetics (KRYS)?
